Lan-Juan Li to Young Adult
This is a "connection" page, showing publications Lan-Juan Li has written about Young Adult.
Connection Strength
0.217
-
Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS-Cov-2) outside of Wuhan, China: retrospective case series. BMJ. 2020 Feb 19; 368:m606.
Score: 0.023
-
Patients with chronic hepatitis C receiving sofosbuvir and ribavirin-based treatment, with or without interferon in Zhejiang, China: An observational study. Medicine (Baltimore). 2018 Sep; 97(38):e12403.
Score: 0.021
-
Development and validation of a novel score for fibrosis staging in patients with chronic hepatitis B. Liver Int. 2018 11; 38(11):1930-1939.
Score: 0.020
-
Diagnostic delay and mortality of active tuberculosis in patients after kidney transplantation in a tertiary care hospital in China. PLoS One. 2018; 13(4):e0195695.
Score: 0.020
-
Hepatitis B virus infection in hilly/mountainous regions of southeastern China: a locality-dependent epidemiology. BMC Infect Dis. 2017 12 29; 17(1):809.
Score: 0.020
-
Hospital-acquired Clostridium difficile infection in Mainland China: A seven-year (2009-2016) retrospective study in a large university hospital. Sci Rep. 2017 08 29; 7(1):9645.
Score: 0.019
-
Open-label phase I clinical trial of Ad5-EBOV in Africans in China. Hum Vaccin Immunother. 2017 09 02; 13(9):2078-2085.
Score: 0.019
-
Non-ALT biomarkers for markedly abnormal liver histology among Chinese persistently normal alanine aminotransferase-chronic hepatitis B patients. World J Gastroenterol. 2017 Apr 21; 23(15):2802-2810.
Score: 0.019
-
Prevalence and influencing factors of hepatitis B among a rural residential population in Zhejiang Province, China: a cross-sectional study. BMJ Open. 2017 04 03; 7(4):e014947.
Score: 0.019
-
Predictive value of serum ALT and T-cell receptor beta variable chain for HBeAg seroconversion in chronic hepatitis B patients during tenofovir treatment. Medicine (Baltimore). 2017 Mar; 96(10):e6242.
Score: 0.019
-
Clinical characteristics of different subtypes and risk factors for the severity of illness in patients with COVID-19 in Zhejiang, China. Infect Dis Poverty. 2020 Jul 08; 9(1):85.
Score: 0.006
-
Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020 04 30; 382(18):1708-1720.
Score: 0.006
-
Sofosbuvir plus ribavirin with or without peginterferon for the treatment of hepatitis C virus: Results from a phase 3b study in China. J Gastroenterol Hepatol. 2018 Jun; 33(6):1168-1176.
Score: 0.005